ATC Group: C01DX22 Vericiguat

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of C01DX22 in the ATC hierarchy

Level Code Title
1 C Cardiovascular system
2 C01 Cardiac therapy
3 C01D Vasodilators used in cardiac diseases
4 C01DX Other vasodilators used in cardiac diseases
5 C01DX22

Active ingredients in C01DX22

Active Ingredient Description
Vericiguat

Vericiguat is a stimulator of soluble guanylate cyclase (sGC). Heart failure is associated with impaired synthesis of nitric oxide (NO) and decreased activity of its receptor, sGC. The pharmacodynamic effects of vericiguat are consistent with the mode of action of a sGC stimulator resulting in smooth muscle relaxation and vasodilation.

Related product monographs

Title Information Source Document Type  
VERQUVO Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

Austria (AT)

Croatia (HR)

Ecuador (EC)

Estonia (EE)

Finland (FI)

France (FR)

Ireland (IE)

Israel (IL)

Italy (IT)

Japan (JP)

Lithuania (LT)

Poland (PL)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.